medigraphic.com
ISSN 1561-302X (Print)

2014, Number 4

<< Back Next >>

Rev cubana med 2014; 53 (4)

Association between chronic hepatitis C virus infection and non-Hodgkin B cell lymphoma

Dorta GZ, Arús SER, Calzadilla BL

Language: Spanish
References: 50
Page: 468-477
PDF size: 89.72 Kb.


ABSTRACT

170 million people are estimated to be infected with hepatitis C virus (HCV) worldwide. The persistence of the virus in the body is due to its ability to mutate and alterations in the immune response that occurs. There are theories linking this virus lymphoma genesis. The relative risk of HCV-infected patients suffering from non-Hodgkin lymphoma is 2-4 times higher than in uninfected subjects. This association has geographic variability. Countries where the association is stronger are Italy, Japan, and the United States, and it is lesser in Canada and northern Europe. Lymphoma of the marginal zone in B cells and lymphoplasmacytic are the most well-informed in association with HCV. Indolent non-Hodgkin lymphomas associated with HCV can be treated with antiviral therapy, but the aggressive forms require specific immunochemotherapy. Hepatitis C has been shown to be a significant risk factor for hepatic toxicity in patients needing chemotherapy.


REFERENCES

  1. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244(4902):359-62.

  2. Kagawa T, Keeffe EB. Long-TermEffects of Antiviral Therapy in Patients with Chronic Hepatitis C. Res Hepat Treat. 2010;2010:562-78. doi: 10.1155/2010/562578.

  3. Savino B, Facciotto C. The natural course of HCV infection and the need for treatment. Ann Hepatology. 2008;7(2):114-9.

  4. Ramia S, Eid-Fares J. Distribution of hepatitis C virus genotypes in the Middle East. Int J Infect Dis. 2006;10(4):272-7. Epub 2006 Mar 27.

  5. Martell M, Gómez J, Esteban JI, Sauleda S, Quer J, Cabot B, et al. Highthroughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA. J Clin Microbiol. 1999;37(2):327-32.

  6. Padrón G, Roca R, Jameel S, Arús E, Rivera L. The Hepatitis C virus infection in Cuba. Antibody pattern and genotypes. Biotecnología Aplicada. 1995;12:93.

  7. Chen SL, Morgan TR. The Natural History of Hepatitis C Virus (HCV) Infection. International J Med Sci. 2006;3(2):47-52.

  8. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000;132:296-305.

  9. Diago M. ¿Mejora el tratamiento antiviral el curso clínico de la cirrosis por virus de la hepatitis C? Gastroenterol Hepatol. 2007;30:85-92.

  10. Arús Soler E. Historia natural de la infección por el virus de la hepatitis C. Rev Cubana Med. ene.-mar. 2006;45(1). [citado 18 nov 2014] Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034- 75232006000100006&lng=es&nrm=iso

  11. Morishima C, Paschal DM, Wang CC, Yoshihara CS, Wood BL, Yeo AE, et al. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology. 2006;43(3):573-80.

  12. Jinushi M, Takehara T, Kanto T, Tatsumi T, Groh V, Spies T, et al. Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection. J Inmunol. 2003;170(3):1249-56.

  13. Koziel MJ. NK cells: natural born killers in the conflict between humans and HCV. Hepatology. 2006;43(3):395-7.

  14. Sarobe P, Lasarte JJ, Casares N, López-Díaz de Cerio A, Baixeras E, Labarga Peta ll. Abnormal priming of CD4 (+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol. 2002;76(10):5062-70. Erratum in: J Virol. 2004;138(1):193.

  15. Lechner F, Wong KHD, Dunbar PR, Chapman R, Chung R T, Dohrenwend P, et al. Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus. J Exp Med. 2000 May 1;191(9):1499-512.

  16. García-Buey L, González-Mateos F, Moreno-Otero R. Manifestaciones extrahepáticas de la infección por VHC. Gastroenterol Hepatol. 2006;29(Supl 2):168-74.

  17. 17. Ferri C, Caracciolo F, Zignego AL, La Civita L, Monti M, Longombardo G, et al. Hepatitis C virus infection in patients with non-Hodgkin’s lymphoma. Br J Haematol. 1994;88(2):392-4.

  18. Pozzato G, Mazzaro C, Crovatto M, et al. Lowgrade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood. 1994;84(9):3047-53.

  19. Arcaini L, Varettoni M, Boveri E, Orlandi E, Rattotti S, Zibellini S, et al. Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2011;11(1):103-5. doi: 10.3816/CLML.2011.n.020.

  20. Chuang SS, Liao YL, Chang ST, Hsieh YC, Kuo SY, Lu CL, et al. Hepatitis C virus infection is significantly associated with malignant lymphoma in Taiwan, particularly with nodal and splenic marginal zone lymphomas. J Clin Pathol. 2010;63(7):595-8.

  21. Nieters A, Kallinowski B, Brennan P, Ott M, Maynadié M, Benavente Y, et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology. 2006;131(6):1879-86. Epub 2006 Sep 20.

  22. Muller HM, Kallinowski B, Solbach C, Theilmann L, Goeser T, Pfaff E. Blymphocytes are predominantely involved in viral propagation of hepatitis C virus. Archives of Virology Supplementum. 1994;9:307-16.

  23. Ferrís Tortajada J, García Castell J, Berbel Tornero O, Clar Gimeno S. Factores de riesgo para los linfomas no hodgkinianos. An Pediatr. 2001;55(3):230-8.

  24. Muratori L, Gibellini D, Lenzi M, Cataleta M, Muratori P, Morelli MC, et al. Quantification of hepatitis C virus-infected cells by in situ reverse transcriptasepolymerase chain reaction. Blood. 1996;88(7):2768-74.

  25. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science. 1998;282(5390):938-41.

  26. Machida K, Cheng KTN, Sung VMH, et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci USA. 2004;101(12):4262-7.

  27. Gisbert JP, García-Buey L, Pajares JM, Moreno-Otero R. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther. 2005;21:653-62.

  28. Vallisa D, Bernuzzi P, Arcaini L, Sacchi S, Callea V, Marasca R, et al. Role of antihepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a multicenter Italian experience. J Clin Oncol. 2005;23:468-73.

  29. Romero-Gómez M, García-Romero D. Hepatitis C: crioglobulinemia y linfoma no-Hodgkin. Rev Esp Enferm Dig. mar. 2008;100(3):164-70.

  30. Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: A meta-analysis of epidemiological studies. Cancer Sci. 2004;95:745-52.

  31. Gisbert JP, García-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: Systematic review and metaanalysis. Gastroenterol. 2003;125(6):1723-32.

  32. Mazzaro C, Tirelli U, Pozzato G. Hepatitis C virus and non-Hodgkin's lymphoma 10 years later. Dig Liver Dis. 2005;37:219-26.

  33. Negri E, Little D'Anna, Boiocchi M, Vecchia C, Franceschi S. B-cell non- Hodgkin's lymphoma and hepatitis C virus infection: A systematic review. Intern J Cancer. 2004;111(1):1-8.

  34. Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, Sanpaolo MG, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas an Italian multicenter case-control study. Blood. 1 august 2003;102(3):996-9.

  35. Nieters A, Kallinowski B, Brennan P, Ott M, Maynadié M, Benavente Y, et al. Hepatitis C and Risk of Lymphoma: Results of the European Multicenter Case- Control Study EPILYMPH. Gastroenterology. 2006;131(6):1879-86.

  36. Ambrosetti A, Zanotti R, Pattaro C, et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection. Br J Haematol. 2004;126:43-9.

  37. Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer. 2004;100:107-15.

  38. Maio G, D’Argenio P, Stroffolini T, et al. Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town. J Hepatol. 2000;33:116-20.

  39. Osella AR, Sonzogni L, Cavallini A, et al. Molecular epidemiology of hepatitis C virus infection in an area of hyperendemicity in southern Italy: a population-based study. J Clin Microbiol. 1999;37:2371-2.

  40. Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut. 1999;44:874-9.

  41. Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol. 2013;59:169-77.

  42. Paulli M, Arcaini L, Lucioni M, Boveri E, Capello D, Passamonti F, et al. Subcutaneous ‘lipoma-like’ B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. Ann Oncol. 2010;21:1189-95.

  43. Mazzaro C, De Re V, Spina M, Dal Maso L, Festini G, Comar C, et al. Pegylatedinterferon plus ribavirin for HCV positive indolent non-Hodgkin lymphomas. Br J Haematol. 2009;145:255-7.

  44. La Mura V, De Renzo A, Perna F, D’Agostino D, Masarone M, Romano M, et al. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV positive non-Hodgkin’s lymphoma. J Hepatol. 2008;49:557-63.

  45. Musto P, Dell’Olio M, La Sala A, Mantuano S, Cascavilla N. Diffuse B-large cell lymphomas (DBLCL) with hepatitis-C virus (HCV) infection: clinical outcome and preliminary results of a pilot study combining R-CHOP with antiviral therapy. Blood. 2005;106:688a.

  46. Besson C, Canioni D, Lepage E, Pol S, Morel P, Lederlin P, et al. Characteristics and Outcome of Diffuse Large B-Cell Lymphoma in Hepatitis C Virus–Positive Patients in LNH 93 and LNH 98 Groupe d’Etude des Lymphomes de l’Adulte Programs. J Clin Oncology. 2006;24(6):953-60.

  47. Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet. 1996;347:92-93.

  48. Kawatani T, Suou T, Tajima F, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol. 20014;67:45-50.

  49. Locasciulli A, Bruno B, Alessandrino EP, et al. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/ hepatitis C virus (HCV) positive recipients: A retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant. 2003;31:295-300.

  50. Daisuke Ennishi, Yoshinobu Maeda, Nozomi Niitsu, Minoru Kojima, Koji Izutsu, Jun Takizawa, et al. Hepatic toxicity and prognosis in hepatitis C virus–infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood. 2010;116(24):5119-25.




2020     |     www.medigraphic.com